ketamine has been researched along with Drug Refractory Epilepsy in 11 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test ketamine infusion efficacy in the treatment of super-refractory status epilepticus (SRSE), we studied patients with SRSE who were treated with ketamine retrospectively." | 7.96 | Ketamine to treat super-refractory status epilepticus. ( Agarwal, S; Alkhachroum, A; Chiu, WT; Claassen, J; Connolly, ES; Der-Nigoghossian, CA; Doyle, K; Kromm, J; Letchinger, R; Massad, N; Mathews, E; Park, S; Roh, D; Rubinos, C; Velazquez, A, 2020) |
| "The aim was to describe the safety and efficacy of (S)-ketamine [(S)-KET] in a series of patients with refractory and super-refractory status epilepticus (RSE and SRSE) in a specialized neurological intensive care unit (NICU)." | 7.83 | (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study. ( Butz, K; Dobesberger, J; Höfler, J; Kalss, G; Kuchukhidze, G; Leitinger, M; Novak, H; Pilz, G; Rohracher, A; Taylor, A; Trinka, E; Zimmermann, G, 2016) |
| "Ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist that has been safely used for the treatment of refractory SE in adults and children." | 7.01 | Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. ( Brisca, G; Buratti, S; Giacheri, E; Mancardi, MM; Moscatelli, A; Nobili, L; Palmieri, A; Riva, A; Striano, P; Tibaldi, J, 2023) |
| "Ketamine is a noncompetitive antagonist of glutamatergic N-methyl-d-aspartate (NMDA) receptors." | 6.52 | Ketamine for the treatment of refractory status epilepticus. ( Fang, Y; Wang, X, 2015) |
| "To test ketamine infusion efficacy in the treatment of super-refractory status epilepticus (SRSE), we studied patients with SRSE who were treated with ketamine retrospectively." | 3.96 | Ketamine to treat super-refractory status epilepticus. ( Agarwal, S; Alkhachroum, A; Chiu, WT; Claassen, J; Connolly, ES; Der-Nigoghossian, CA; Doyle, K; Kromm, J; Letchinger, R; Massad, N; Mathews, E; Park, S; Roh, D; Rubinos, C; Velazquez, A, 2020) |
| "The aim was to describe the safety and efficacy of (S)-ketamine [(S)-KET] in a series of patients with refractory and super-refractory status epilepticus (RSE and SRSE) in a specialized neurological intensive care unit (NICU)." | 3.83 | (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study. ( Butz, K; Dobesberger, J; Höfler, J; Kalss, G; Kuchukhidze, G; Leitinger, M; Novak, H; Pilz, G; Rohracher, A; Taylor, A; Trinka, E; Zimmermann, G, 2016) |
| "Ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist that has been safely used for the treatment of refractory SE in adults and children." | 3.01 | Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. ( Brisca, G; Buratti, S; Giacheri, E; Mancardi, MM; Moscatelli, A; Nobili, L; Palmieri, A; Riva, A; Striano, P; Tibaldi, J, 2023) |
| "Ketamine is an N-methyl-d-aspartate (NMDA) receptor antagonist that works by binding to the phencyclidine-binding site, thereby blocking influx of cations through the NMDA receptor channel." | 2.66 | Are Ketamine Infusions a Viable Therapeutic Option for Refractory Neonatal Seizures? ( Bingham, W; Huntsman, RJ; Strueby, L, 2020) |
| "Ketamine is a noncompetitive antagonist of glutamatergic N-methyl-d-aspartate (NMDA) receptors." | 2.52 | Ketamine for the treatment of refractory status epilepticus. ( Fang, Y; Wang, X, 2015) |
| "Ketamine was used in most severe cases." | 1.42 | Preliminary results of the global audit of treatment of refractory status epilepticus. ( Ferlisi, M; Grade, M; Hocker, S; Shorvon, S; Trinka, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ioku, T | 1 |
| Inoue, T | 1 |
| Kuki, I | 1 |
| Imai, K | 1 |
| Yamamoto, A | 1 |
| Cho, M | 1 |
| Buratti, S | 1 |
| Giacheri, E | 1 |
| Palmieri, A | 1 |
| Tibaldi, J | 1 |
| Brisca, G | 1 |
| Riva, A | 1 |
| Striano, P | 1 |
| Mancardi, MM | 1 |
| Nobili, L | 1 |
| Moscatelli, A | 1 |
| Huntsman, RJ | 1 |
| Strueby, L | 1 |
| Bingham, W | 1 |
| Borsato, GS | 1 |
| Siegel, JL | 1 |
| Rose, MQ | 1 |
| Ojard, M | 1 |
| Feyissa, AM | 1 |
| Quinones-Hinojosa, A | 1 |
| Jackson, DA | 1 |
| Rogers, ER | 1 |
| Freeman, WD | 1 |
| Alkhachroum, A | 1 |
| Der-Nigoghossian, CA | 1 |
| Mathews, E | 1 |
| Massad, N | 1 |
| Letchinger, R | 1 |
| Doyle, K | 1 |
| Chiu, WT | 1 |
| Kromm, J | 1 |
| Rubinos, C | 1 |
| Velazquez, A | 1 |
| Roh, D | 1 |
| Agarwal, S | 1 |
| Park, S | 1 |
| Connolly, ES | 1 |
| Claassen, J | 1 |
| Mishra, BR | 1 |
| Biswas, T | 1 |
| Nath, S | 1 |
| Jha, M | 1 |
| Mishra, S | 1 |
| Mohapatra, D | 1 |
| Caputo, D | 1 |
| Iorio, R | 1 |
| Vigevano, F | 1 |
| Fusco, L | 1 |
| Ferlisi, M | 1 |
| Hocker, S | 1 |
| Grade, M | 1 |
| Trinka, E | 2 |
| Shorvon, S | 1 |
| Fang, Y | 1 |
| Wang, X | 1 |
| Sabharwal, V | 1 |
| Ramsay, E | 1 |
| Martinez, R | 1 |
| Shumate, R | 1 |
| Khan, F | 1 |
| Dave, H | 1 |
| Iwuchukwu, I | 1 |
| McGrade, H | 1 |
| Höfler, J | 1 |
| Rohracher, A | 1 |
| Kalss, G | 1 |
| Zimmermann, G | 1 |
| Dobesberger, J | 1 |
| Pilz, G | 1 |
| Leitinger, M | 1 |
| Kuchukhidze, G | 1 |
| Butz, K | 1 |
| Taylor, A | 1 |
| Novak, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Combined Ketamine and Midazolam for Treatment of Generalized Convulsive Status Epilepticus in Children .[NCT05779657] | Phase 2/Phase 3 | 144 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ketamine and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children.
Topics: Animals; Anticonvulsants; Benzodiazepines; Drug Resistant Epilepsy; Ketamine; Status Epilepticus; Va | 2023 |
Are Ketamine Infusions a Viable Therapeutic Option for Refractory Neonatal Seizures?
Topics: Drug Resistant Epilepsy; Excitatory Amino Acid Antagonists; Humans; Infant, Newborn; Infant, Newborn | 2020 |
Ketamine in seizure management and future pharmacogenomic considerations.
Topics: Anticonvulsants; Disease Management; Drug Resistant Epilepsy; Drug Therapy, Combination; Excitatory | 2020 |
Ketamine for the treatment of refractory status epilepticus.
Topics: Animals; Anticonvulsants; Drug Resistant Epilepsy; Humans; Ketamine; Status Epilepticus | 2015 |
7 other studies available for ketamine and Drug Refractory Epilepsy
| Article | Year |
|---|---|
[A case of febrile infection-related epilepsy syndrome requiring prolonged intensive care management: a trial of intravenous ketamine and intrathecal dexamethasone therapy].
Topics: Adolescent; Critical Care; Dexamethasone; Drug Resistant Epilepsy; Encephalitis; Epileptic Syndromes | 2022 |
Ketamine to treat super-refractory status epilepticus.
Topics: Anticonvulsants; Brain; Drug Resistant Epilepsy; Electroencephalography; Female; Humans; Ketamine; M | 2020 |
Electroconvulsive Therapy With Ketamine as Induction Agent in Refractory Epilepsy With Atypical Postictal Psychosis: A Case Report.
Topics: Anesthetics, Dissociative; Drug Resistant Epilepsy; Electroconvulsive Therapy; Electroencephalograph | 2021 |
Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABA
Topics: Adolescent; Anticonvulsants; Autoantibodies; Drug Resistant Epilepsy; Encephalitis; Epileptic Syndro | 2018 |
Preliminary results of the global audit of treatment of refractory status epilepticus.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anesthesia, General; Anesthetics, Dissociat | 2015 |
Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics, Dissociative; Anesthetics, Intravenous; Chi | 2015 |
(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.
Topics: Aged; Anesthetics; Anticonvulsants; Drug Resistant Epilepsy; Electroencephalography; Excitatory Amin | 2016 |